Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Genome Med ; 3(10): 64, 2011 Oct 04.
Article in English | MEDLINE | ID: mdl-21970596

ABSTRACT

BACKGROUND: Pharmacogenetic testing holds major promise in allowing physicians to tailor therapy to patients based on genotype. However, there is little data on the impact of pharmacogenetic test results on patient and clinician choice of therapy. CYP2D6 testing among tamoxifen users offers a potential test case of the use of pharmacogenetic testing in the clinic. We evaluated the effect of CYP2D6 testing in clinical practice to determine whether genotype results affected choice of hormone therapy in a prospective cohort study. METHODS: Women planning to take or currently taking tamoxifen were considered eligible. Participants were enrolled in an informational session that reviewed the results of studies of CYP2D6 genotype on breast cancer recurrence. CYP2D6 genotyping was offered to participants using the AmpliChip CYP450 Test. Women were classified as either poor, intermediate, extensive or ultra-rapid metabolizers. Results were provided to clinicians without specific treatment recommendations. Follow-up was performed with a structured phone interview 3 to 6 months after testing to evaluate changes in medication. RESULTS: A total of 245 women were tested and 235 completed the follow-up survey. Six of 13 (46%) women classified as poor metabolizers reported changing treatment compared with 11 of 218 (5%) classified as intermediate, extensive or ultra-rapid metabolizers (P < 0.001). There was no difference in treatment choices between women classified as intermediate and extensive metabolizers. In multi-variate models that adjusted for age, race/ethnicity, educational status, method of referral into the study, prior knowledge of CYP2D6 testing, the patients' CYP2D6 genotype was the only significant factor that predicted a change in therapy (odds ratio 22.8; 95% confidence interval 5.2 to 98.8). Genetic testing did not affect use of co-medications that interact with CYP2D6. CONCLUSIONS: CYP2D6 genotype testing led to changes in therapy among poor metabolizers, even in the absence of definitive data that an alternative medicine improved outcomes. Pharmacogenetic testing can affect choice of therapy, even in the absence of definitive data on clinical impact.

2.
Am J Med Genet C Semin Med Genet ; 157C(2): 136-46, 2011 May 15.
Article in English | MEDLINE | ID: mdl-21495172

ABSTRACT

The RASopathies, one of the largest groups of multiple congenital anomaly syndromes known, are caused by germline mutations in various genes encoding components of the Ras/mitogen-activated protein kinase (MAPK) pathway. The RASopathies have many overlapping characteristics, including craniofacial manifestations, cardiac malformations, cutaneous, musculoskeletal, gastrointestinal, and ocular abnormalities, neurocognitive impairment, hypotonia, and an increased risk of developing cancer. Costello syndrome (CS) and cardio-facio-cutaneous (CFC) syndrome are two of the more rare RASopathies. CS is caused by activating mutations in HRAS, and CFC is caused by dysregulation of signaling in the Ras/MAPK pathway due to mutations in BRAF, MEK1, or MEK2. The Ras/MAPK pathway, which has been well-studied in cancer, is an attractive target for inhibition in the treatment of various malignancies utilizing small molecule therapeutics that specifically inhibit the pathway. With many inhibitors of the Ras/MAPK pathway in clinical trials, the notion of using these molecules to ameliorate developmental defects in CS and CFC is under consideration. CS and CFC, like other syndromes in their class, have a progressive phenotype and may be amenable to inhibition or normalization of signaling.


Subject(s)
Clinical Trials as Topic/methods , Costello Syndrome/genetics , Neurofibromatosis 1/genetics , Proto-Oncogene Proteins p21(ras)/genetics , Research Design , Signal Transduction/genetics , Costello Syndrome/drug therapy , Ectodermal Dysplasia/drug therapy , Ectodermal Dysplasia/genetics , Facies , Failure to Thrive/drug therapy , Failure to Thrive/genetics , Farnesyltranstransferase/antagonists & inhibitors , Heart Defects, Congenital/drug therapy , Heart Defects, Congenital/genetics , Humans , MAP Kinase Kinase 1/antagonists & inhibitors , Public-Private Sector Partnerships , raf Kinases/antagonists & inhibitors
3.
Am J Med Genet A ; 152A(1): 4-24, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20014119

ABSTRACT

The RASopathies are a group of genetic syndromes caused by germline mutations in genes that encode components of the Ras/mitogen-activated protein kinase (MAPK) pathway. Some of these syndromes are neurofibromatosis type 1, Noonan syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, LEOPARD syndrome and Legius syndrome. Their common underlying pathogenetic mechanism brings about significant overlap in phenotypic features and includes craniofacial dysmorphology, cardiac, cutaneous, musculoskeletal, GI and ocular abnormalities, and a predisposition to cancer. The proceedings from the symposium "Genetic Syndromes of the Ras/MAPK Pathway: From Bedside to Bench and Back" chronicle the timely and typical research symposium which brought together clinicians, basic scientists, physician-scientists, advocate leaders, trainees, students and individuals with Ras syndromes and their families. The goals, to discuss basic science and clinical issues, to set forth a solid framework for future research, to direct translational applications towards therapy and to set forth best practices for individuals with RASopathies were successfully meet with a commitment to begin to move towards clinical trials.


Subject(s)
MAP Kinase Signaling System , ras Proteins/metabolism , Humans , Syndrome
5.
Biotechnol J ; 1(3): 282-8, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16897708

ABSTRACT

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan degradation enzyme that is emerging as an important drug target. IDO is expressed by many human tumors to help them escape immune detection, and it has been implicated in depression and in the formation of senile nuclear cataracts. There is a need for potent and selective IDO inhibitors for use in research and as lead compounds for drug development. We show that expression of human IDO in a Saccharomyces cerevisiae tryptophan auxotroph restricts yeast growth in the presence of low tryptophan concentrations and that inhibition of IDO activity can restore growth. We use this assay to screen for IDO inhibitors in collections of pure chemicals and crude natural extracts. We identify NSC 401366 (imidodicarbonimidic diamide, N-methyl-N'-9-phenanthrenyl-, monohydrochloride) as a potent nonindolic IDO inhibitor (Ki=1.5 +/- 0.2 microM) that is competitive with respect to tryptophan. We also use this assay to identify the active compound caulerpin from a crude algal extract. The yeast growth restoration assay is simple and inexpensive. It combines desirable attributes of cell- and target-based screens and is an attractive tool for chemical biology and drug screening.


Subject(s)
Biological Assay/methods , Drug Evaluation, Preclinical/methods , Enzyme Inhibitors/administration & dosage , Indoleamine-Pyrrole 2,3,-Dioxygenase/antagonists & inhibitors , Saccharomyces cerevisiae/cytology , Saccharomyces cerevisiae/physiology , Cell Proliferation/drug effects , Humans , Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Recombinant Proteins/metabolism , Saccharomyces cerevisiae/drug effects
6.
Trends Pharmacol Sci ; 23(12): 544-7, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12457767

ABSTRACT

Yeast expands its role from eukaryotic genetics and genomics to drug discovery.


Subject(s)
Drug Design , Genome, Fungal , Genomics/methods , Protein Biosynthesis , Yeasts/genetics , Genomics/trends , Humans , Yeasts/growth & development
SELECTION OF CITATIONS
SEARCH DETAIL
...